BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol 2017;10:707-16. [PMID: 28460547 DOI: 10.1080/17512433.2017.1323633] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Duraisamy GS, Bhosale D, Lipenská I, Huvarova I, Růžek D, Windisch MP, Miller AD. Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going? Viruses 2020;12:E998. [PMID: 32906840 DOI: 10.3390/v12090998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Chan C, Foster ST, Chan KG, Cacace MJ, Ladd SL, Sandum CT, Wright PT, Volmert B, Yang W, Aguirre A, Li W, Wright NT. Repositioned Drugs for COVID-19-the Impact on Multiple Organs. SN Compr Clin Med 2021;:1-18. [PMID: 33898925 DOI: 10.1007/s42399-021-00874-8] [Reference Citation Analysis]
3 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
4 De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochem Pharmacol 2018;153:2-11. [PMID: 29225131 DOI: 10.1016/j.bcp.2017.11.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
5 Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol 2020;55:811-23. [PMID: 32666200 DOI: 10.1007/s00535-020-01698-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Séhonou J, Kpossou AR, Amanda TO, Sokpon CNM, Vignon RK, Vigan J. [Hepatitis B and renal failure: prevalence and associated factors in National University Hospital Center of Cotonou]. Pan Afr Med J 2018;31:121. [PMID: 31037181 DOI: 10.11604/pamj.2018.31.121.16498] [Reference Citation Analysis]
7 Chen X, Luo W, Wang Y, Li Z, Ma X, Peng AY. Efficient Synthesis of Phosphonamidates through One-Pot Sequential Reactions of Phosphonites with Iodine and Amines. Chemistry 2020;26:14474-80. [PMID: 32776399 DOI: 10.1002/chem.202002934] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
9 Yeh ML, Liang PC, Trinh S, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide. J Formos Med Assoc 2021:S0929-6646(21)00431-9. [PMID: 34625346 DOI: 10.1016/j.jfma.2021.09.009] [Reference Citation Analysis]
10 Takayama H, Komura T, Kagaya T, Sugimoto S, Orita N, Asahina Y, Nishikawa M, Ohta H, Kaneko S, Unoura M. Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B. Can J Gastroenterol Hepatol 2021;2021:3259833. [PMID: 34422709 DOI: 10.1155/2021/3259833] [Reference Citation Analysis]
11 Kauppinen KJ, Kivelä P, Sutinen J. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. AIDS Patient Care STDS 2019;33:500-6. [PMID: 31742421 DOI: 10.1089/apc.2019.0236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
12 Lengauer H, Makuc D, Šterk D, Perdih F, Pichler A, Trdan Lušin T, Plavec J, Časar Z. Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates. Pharmaceutics 2020;12:E342. [PMID: 32290280 DOI: 10.3390/pharmaceutics12040342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int 2018;38 Suppl 1:102-14. [PMID: 29427479 DOI: 10.1111/liv.13656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
14 Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, Gao Z, Fu M, Yan T, Yang Y, Li J, Liu J, Chen T, Zhao Y, He Y. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis 2021;21:567. [PMID: 34126939 DOI: 10.1186/s12879-021-06237-x] [Reference Citation Analysis]
15 Tonon M, Piano S, Romano A, Fasolato S, Stanco M, Pilutti C, Pontisso P, Mareso S, Gambino C, Sartori L, Angeli P. Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir. Eur J Gastroenterol Hepatol 2018;30:284-90. [PMID: 29309397 DOI: 10.1097/MEG.0000000000001051] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Pileggi E, Serpi M, Andrei G, Schols D, Snoeck R, Pertusati F. Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. Bioorg Med Chem 2018;26:3596-609. [PMID: 29880251 DOI: 10.1016/j.bmc.2018.05.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Singh US, Mulamoottil VA, Chu CK. 2′-Fluoro-6′-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants. Med Res Rev 2018;38:977-1002. [DOI: 10.1002/med.21490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Guvenir M, Arikan A. Hepatitis B Virus: From Diagnosis to Treatment. Pol J Microbiol 2020;69:391-9. [PMID: 33574867 DOI: 10.33073/pjm-2020-044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Fu Y, Duan F, Du Z. Visible Light Driven Oxidative Coupling of Amines and P(O)−H/P−OR Compounds under Photocatalyst‐Free Conditions. Asian J of Organic Chemis 2021;10:1071-5. [DOI: 10.1002/ajoc.202100052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pribut N, D'Erasmo M, Dasari M, Giesler KE, Iskandar S, Sharma SK, Bartsch PW, Raghuram A, Bushnev A, Hwang SS, Burton SL, Derdeyn CA, Basson AE, Liotta DC, Miller EJ. ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties. J Med Chem 2021;64:12917-37. [PMID: 34459598 DOI: 10.1021/acs.jmedchem.1c01083] [Reference Citation Analysis]
21 Cho YY, Chang Y, Nam JY, Cho H, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. Gut Liver 2020;14:225-31. [PMID: 31060115 DOI: 10.5009/gnl18474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]